Clinical trial
IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients With Pulmonary Arterial Hypertension (PAH)
NCT05036135 is registered in ClinicalTrials.gov with Aerovate Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients With Pulmonary Arterial Hypertension (PAH)
- Lead sponsor
- Aerovate Therapeutics
- Phase
- Phase 2/3
- Overall status
- Terminated
- Start date
- December 2, 2021
- Completion date
- August 9, 2024
- Enrollment
- 202 (actual)
- Sites
- 128
Conditions
As the registry lists them; a condition with its own page is linked.